fluoxetine + modafinil

Fluoxetine + modafinil is a combination of two pharmaceutical agents used together, primarily investigated for the treatment of major depressive disorder. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting its reuptake, thereby exerting antidepressant effects. Modafinil is a wakefulness-promoting agent that acts as a central nervous system stimulant, with mechanisms believed to involve modulation of several neurotransmitter systems including dopamine and norepinephrine transporters. Clinical studies have shown that the combination can be more effective than fluoxetine alone in reducing symptoms of major depression, with similar tolerability and side effect profiles[2][4]. This combination has been explored particularly for patients experiencing fatigue or residual symptoms despite SSRI monotherapy.